Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
Alison M. Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M. Bauer, Ning Jin, Susanna V. Ulahannan, Marco Colleoni, Philippe Aftimos, Mark T. A. Donoghue, Ezra Rosen, Vasilisa A. Rudneva, Melinda L. Telli, Susan M. Domchek, Matthew D. Galsky, Margaret Hoyle, Colombe ChappeyRoss Stewart, John A. Blake-Haskins, Timothy A. Yap
Research output: Contribution to journal › Article
Fingerprint
Dive into the research topics of 'Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial'. Together they form a unique fingerprint.